|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
1995-1-23
|
|
pubmed:abstractText |
The antitumor effect of etoposide is increased by maintaining a low blood level, whereas high peak levels may cause myelotoxicity. We investigated whether a constant low blood level could be obtained by the administration of oral etoposide three times daily.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
13
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
191-9
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:7799020-Administration, Oral,
pubmed-meshheading:7799020-Adult,
pubmed-meshheading:7799020-Aged,
pubmed-meshheading:7799020-Aged, 80 and over,
pubmed-meshheading:7799020-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:7799020-Cisplatin,
pubmed-meshheading:7799020-Drug Administration Schedule,
pubmed-meshheading:7799020-Etoposide,
pubmed-meshheading:7799020-Female,
pubmed-meshheading:7799020-Humans,
pubmed-meshheading:7799020-Leukopenia,
pubmed-meshheading:7799020-Lung Neoplasms,
pubmed-meshheading:7799020-Male,
pubmed-meshheading:7799020-Middle Aged,
pubmed-meshheading:7799020-Regression Analysis
|
|
pubmed:year |
1995
|
|
pubmed:articleTitle |
Clinical and pharmacologic analysis of hyperfractionated daily oral etoposide.
|
|
pubmed:affiliation |
Department of Internal Medicine, Japanese Red Cross Nagoya First Hospital.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
